These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32961860)

  • 1. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
    Nasykhova YA; Tonyan ZN; Mikhailova AA; Danilova MM; Glotov AS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 7. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of diabetes: therapies for type 2 diabetes.
    Tsoutsouki J; Wunna W; Chowdhury A; Chowdhury TA
    Postgrad Med J; 2020 Oct; 96(1140):610-618. PubMed ID: 32467106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
    Tahrani AA; Barnett AH; Bailey CJ
    Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 14. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can genetics improve precision of therapy in diabetes?
    Groop L; Storm P; Rosengren A
    Trends Endocrinol Metab; 2014 Sep; 25(9):440-3. PubMed ID: 25028244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Weight Considerations in the Management of Type 2 Diabetes.
    Apovian CM; Okemah J; O'Neil PM
    Adv Ther; 2019 Jan; 36(1):44-58. PubMed ID: 30465123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.
    Bongaerts B; Kollhorst B; Kuss O; Pigeot I; Rathmann W
    Exp Clin Endocrinol Diabetes; 2022 Sep; 130(9):587-595. PubMed ID: 34942670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of novel glucose-lowering drugs.
    Rathmann W; Bongaerts B
    Diabetologia; 2021 Jun; 64(6):1201-1212. PubMed ID: 33594477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.